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High level of serum apolipoprotein A-I is a
favorable prognostic factor for overall
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Abstract
Background: Noninvasive prognostic tools for esophageal squamous cell carcinoma (ESCC) are urgently needed.
Serum lipids and lipoproteins are used for the prognosis of certain diseases; however, the prognostic value of
serum apolipoprotein A-I (ApoA-I) in ESCC has not been described.
Methods: Pre-treatment serum lipids and lipoprotein concentrations (including ApoA-I, Apo-B, HDL-C, LDL-C, TC
and TG) were analyzed retrospectively and compared between 210 patients with ESCC and 219 healthy controls.
The prognostic significance of serum lipids and lipoproteins was determined by univariate and multivariate Cox
hazard models in ESCC.
Results: Clinical characteristics (age, sex, pT status, pN status, pM status, pTNM status, histological differentiation or
alcohol index) had no influence on baseline ApoA-I level. Serum ApoA-I, HDL-C, LDL-C, and TC levels were
significantly lower and Apo-B was significantly higher in ESCC patients than in normal controls. On univariate
analysis, ApoA-I, alcohol index, pT status, pN status and pTNM status were associated with significantly poor
survival, and ApoA-I (p = 0.039), alcohol index (p = 0.037) and pTNM status (p = 0.000) were identified as prognostic
factors associated with shorter survival in the multivariate analysis.
Conclusions: Overall survival was shorter in ESCC patients with decreased pre-treatment ApoA-I levels. Our findings
suggest that serum ApoA-I level should be evaluated as a predictor of survival in patients with ESCC.
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Background
Esophageal squamous cell carcinoma (ESCC), the pre-
dominant histologic type of esophageal cancer, is one of
the most lethal malignancies of the digestive system and
the sixth leading cause of cancer mortality worldwide [1,
2]. Despite improvements in treatment strategies,
including surgical techniques and adjuvant chemoradia-
tion, the overall 5-year survival rate of ESCC patients
treated with surgery alone is less than 20 % [3, 4]. In
recent years, many serum biomarkers, such as SCC,
CYFRA21-1, and CEA, have been used to predict the
survival of ESCC patents. However, these markers have
limited sensitivity and specificity and are not entirely
reliable [5–7]. Therefore, the identification of accurate
biomarkers for ESCC is necessary to improve the clinical
outcome of patients.
Abnormal levels of lipids have been shown to be
closely correlated with tumor progression in several
cancers [8, 9]. Cholesterol synthesis is enhanced in
cancer cells compared with normal cells, as tumor cells
need excess cholesterol and cholesterol biosynthesis
pathway intermediates to maintain a high level of
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proliferation [10]. Evidence for the activation of lipid
metabolism in tumor cells can be provided by quantifying
the products of lipid metabolism such as apolipoprotein
A-I (ApoA-I) in the serum of cancer patients [11–13].
ApoA-I is a major high-density lipoprotein cholesterol
(HDL-C) component in serum, which constitutes approxi-
mately 70 % of the apolipoprotein content of HDL-C par-
ticles [14]. ApoA-I can function as an enzyme cofactor,
receptor ligand, and lipid transfer carrier involved in the
regulation of lipoprotein metabolism [9, 15, 16]. Beyond
the known functions of ApoA-I, it may indirectly promote
tumor survival through the other activation. It is overex-
pressed in patients with recurrent head and neck squa-
mous cell carcinoma [17]. High ApoA-I concentration is
associated with increased risk of cancer, in particular head
and neck squamous cell carcinoma [18], whereas the
prognostic roles of ApoA-I, Apo-B, HDL-C, low-density
lipoprotein cholesterol (LDL-C), total cholesterol (TC),
and triglycerides (TG) remain unclear. ApoA-I is a risk
and prognostic factor in nasopharyngeal carcinoma [19];
however, its prognostic value remains unclear in ESCC.
To clarify the association between lipid profiles and
ESCC, this study was designed to elucidate the associ-
ations between alterations of in vivo lipid metabolism
and the occurrence of ESCC by measuring the levels
of a number of relevant lipids in the pre-therapy
serum of patients with ESCC in comparison with
those of healthy participants.
Methods
Patients
Between January 2007 and July 2009, 210 eligible pa-
tients (150 men and 60 women; ages 36–79 years, me-
dian 58 years) diagnosed with ESCC at the Sun Yat-sen
University Cancer Center were enrolled into this retro-
spective study. The demographic details are described in
Table 1. All of the patients met the diagnostic criteria
for ESCC. Exclusion criteria were as follows: (1) patients
treated with medication or taking hormone replacement
therapy or any drugs known to affect lipid metabolism
before serum collection; (2) patients with concomitant
diseases associated with increased serum lipid and lipo-
protein levels (i.e., diabetes, hyperlipidemia, or metabolic
syndrome); (3) other types of malignancy. Based on
medical records, the tumor differentiation grades were
classified according to the World Health Organization
criteria. Stage was recorded based on the American Joint
Committee on Cancer guidelines (2009) [20]. All pa-
tients received treatment. Clinical information, including
demographic data, pathological tumor node metastasis
(pTNM) stage, smoking status, alcohol consumption,
and overall survival (OS) data were available for all pa-
tients. Tobacco index was calculated as cigarettes per
day multiplied by years of smoking, and patients were
divided into two groups: smoking and nonsmoking. Al-
cohol index was assessed as drinking or not drinking. A
total of 219 healthy participants (137 men and 82
women; ages 23–79 years, median 54 years) were
recruited from the physical examination department at
Sun Yat-Sen University Cancer Center.
Prior to use of these serum, informed consent was
obtained from each of the patients and healthy partici-
pants. All of them provided written informed consent.
In our institution, patients were generally followed up
every 3 months in the first years, every 6 months for the
following 2 years, and annually thereafter for patients
without evidence of recurrence. The last follow-up was
in October 2015, inform consent and survival status was
verified again through direct telecommunication with the
patient or their family (performed by The Medical Infor-
mation Unit in our Cancer Center). This study was ap-
proved by the Institute Research Ethics Committee of the
Sun Yat-Sen University Cancer Center, Guangzhou, China.
Laboratory measurements
As part of the physical examination, peripheral blood was
collected from the patients between 7 and 8 a.m., before
treatment, clotted at room temperature, and centrifuged
at 3500 r/min for 8 min. The levels of ApoA-I, Apo-B,
HDL-C, LDL-C, TC, and TG were measured using a Hita-
chi 7600 automatic biochemical analyzer (Hitachi High-
Technologies, Tokyo, Japan). ApoA-I and Apo-B were
measured using immunoturbidimetry; HDL-C and LDL-C
were detected by the selective elimination method (direct
method) and selective protection method, respectively;
serum TC was measured by the CHOD-PAP method and
TC was tested using the GPO-PAP method. All reagents
used in this study were provided by Wako Pure Chemical
Industries, Japan.
Statistical analysis
All statistical tests were performed with SPSS 16.0 for
Windows software (SPSS, Chicago, IL, USA). OS was cal-
culated between the first diagnosis of ESCC and death, or
the date of the last follow-up. Data were expressed as the
mean and standard deviation (mean ± SD), and the correl-
ation between ApoA-I and clinical characteristics was
assessed using the Mann–Whitney U test and χ2 test. The
differences between ESCC patients and healthy donors
were compared using the unpaired Student’s t-test. Uni-
variate and multivariate analyses of clinical variables were
performed using Cox proportional hazards regression
models. The results of this survey were analyzed using the
Kaplan–Meier survival curves with the log-rank test and
proportional hazard model. The correlation between
ApoA-I and alcohol index was analyzed using the Spear-
man rank correlation test. P values < 0.05 were regarded
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as indicating statistically significant differences. All re-
ported P values are two sided.
Results
Relationship of ApoA-I level with clinical characteristics
This study was a retrospective review that included 210
ESCC patients between January 2007 and July 2009. At
the time of the last follow-up, 115 (54.76 %) of the 210
patients had died.
The associations between median serum ApoA-I levels
and clinical variables in 210 ESCC patients and controls
are presented in Table 1. In the entire cohort, age, sex, pT
status, pN status, pM status, pTNM status, histological
differentiation or alcohol index had no influence on base-
line ApoA-I level both in ESCC patients and controls.
Pre-therapy serum levels of lipids in ESCC patients and
healthy controls
The levels of lipids and lipoproteins were compared
between ESCC patients and healthy controls to investigate
lipid abnormalities associated with ESCC (Table 2). The
pre-therapy serum levels of ApoA-I (1.22 ± 0.22 mg/dL),
HDL-C (1.22 ± 0.32 mg/dL), and TC (4.98 ± 0.95 mg/dL)
in ESCC patients were significantly lower than those in
the age and sex matched normal controls (ApoA-I: 1.58 ±
0.24 mg/dL; HDL-C: 1.43 ± 0.33 mg/dL; TC: 5.61 ±
1.07 mg/dL), and the level of Apo-B (1.02 ± 0.25 mg/dL)
Table 1 The levels of ApoA-I between the ESCC patients and healthy controls
Characteristics ESCC p Value Controls p Value
Numbers Median (range) Numbers Median (range)
Age, years 0.973 0.733
<58 102 1.21(0.83–1.64) 105 1.56(0.8–2.32)
≥58 108 1.21(0.71–2.05) 114 1.59(1.23–2.11)
Sex 0.084 0.887
Male 150 1.16(0.71–2.05) 137 1.56(0.8–2.24)
Female 60 1.25(0.81–1.89) 82 1.58(1.05–2.32)
pT status 0.175
pT 1 17 1.15(0.95–1.39)
pT 2 40 1.26(0.88–2.05)
pT 3 128 1.20(0.71–1.84)
pT 4 25 1.12(0.87–1.6)
pN status 0.094
pN 0 114 1.25(0.8–2.05)
pN 1 96 1.16(0.71–1.8)
pM status 0.828
pM 0 197 1.21(0.71–2.05)
pM 1 13 1.16(0.92–1.59)
pTNM status 0.226
Stage I 15 1.15(1.03–1.39)
Stage II 103 1.25(0.8–2.05)
Stage III 80 1.15(0.71–1.8)
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in ESCC patients was higher than that in healthy controls
(0.97 ± 0.25 mg/dL). However, there were no significantly
differences in TG and LDL-C between ESCC patients
(1.26 ± 0.89 and 3.50 ± 0.94) and healthy controls (1.48 ±
1.42 and 3.42 ± 0.98) (Fig. 1).
Univariate and multivariate analysis of clinicopathologic
characteristics and lipids in ESCC patients
To determine the prognostic value of pre-treatment
lipids and lipoproteins in ESCC patients, the clinical
characteristics (including age, gender, tobacco index,
alcohol index, pT status, pN status, pM status, pTNM
status, and histological differentiation) and lipid levels
were subjected to univariate and multivariate analyses.
In the univariate analysis, ApoA-I [hazard ratio (HR):
1.541, p = 0.016], alcohol index (Yes vs. No, HR: 0.65, p =
0.015), pT status (T1-2 vs. T3-4, HR: 0.453, p = 0.001), pN
status (Yes vs. No, HR: 0.416, p = 0.000), pM status (Yes
vs. No, HR: 0.401, p = 0.003), and pTNM status (I–II vs.
III–IV, HR: 0.412, p = 0.000) were associated with signifi-
cantly poor survival (Table 3).
To determine whether these five factors could be used
as independent prognostic factors for survival, they were
subjected to multivariate analysis. Considering the influ-
ence of statistical collinearity, the multivariate model did
not include pT status, pN status, or pM status. The results
showed that ApoA-I (HR: 1.519, p = 0.039), alcohol index
(Yes vs. No, HR: 0.688, p = 0.037) and pTNM status (I–II
vs. III–IV, HR: 0.427, p = 0.000) were significant independ-
ent predictors of favorable OS. Thus, our findings indi-
cated that serum ApoA-I level before therapy may be a
novel independent prognostic factor for ESCC (Fig. 2).
Kaplan–Meier survival analysis of the levels of
independent predictors in ESCC
The Kaplan–Meier method was used to further explore
the prognostic significance of ApoA-I level in ESCC,
which was used to plot the survival curves. In the whole
ESCC cohort, patients with a higher ApoA-I level
showed a significantly better 5-year OS than the lower
Apo-A1 group. The cumulative 5-year survival rate in
the higher ApoA-I group was 48.54 %, whereas it was
Table 2 The levels of lipids between the ESCC patients and
healthy controls
ESCC Normal p Value
Median (range) Median (range)
ApoA-I(g/L) 1.21 0.71–2.05 1.56 0.8–2.25 0.000
ApoB(g/L) 1.00 0.41–1.81 0.96 0.41–1.88 0.042
HDL-C(mmol/L) 1.20 0.39–2.34 1.40 0.68–2.47 0.000
LDL-C(mmol/L) 3.38 1.32–7.09 3.42 1.17–6.11 0.583
TC(mmol/L) 4.89 2.72–7.57 5.59 2.57–8.92 0.000
TG(mmol/L) 1.10 0.38–10.55 1.12 0.4–12.91 0.534
Bold values represent the P-value <0.05, which was considered to be
statistically significant
Fig. 1 Pre-therapy serum levels of lipids in ESCC patients and healthy controls. The serum HDL-C, TC, ApoA-I, ApoB levels in ESCC patients and
healthy controls are plotted as a distribution (a, b, c, d)
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only 30.84 % in the low ApoA-I group. Furthermore, a
high alcohol index and p TNM status were associated
with poor 5-year OS in ESCC patients (Fig. 2).
Discussion
The lack of accurate prognostic biomarkers for patients
with ESCC limits therapeutic development, and the
long-term survival of these patients remains low. There-
fore, the identification of novel prognostic biomarkers
for patients with ESCC is critical. In the present study,
we compared the levels of serum lipids and lipoproteins
(ApoA-I, Apo-B, HDL-C, LDL-C, TC and TG) between
ESCC patients and controls. We found that the levels of
ApoA-I, HDL-C, and TC were significantly lower,
whereas Apo-B was higher in patients with ESCC than
in healthy controls. In addition, OS rates were signifi-
cantly poorer in patients with decreased ApoA-I levels
than in patients with high ApoA-I levels, and this was
independent of other variables predicting the prognosis
of ESCC patients. In addition, alcohol index was an in-
dependent prognostic indicator for ESCC, and pTNM
status was an independent prognostic factor for poor
survival outcome. After adjustment for clinical charac-
teristics, ApoA-I levels were not associated with age,
sex, pT status, pN status, pM status, TNM status, histo-
logical differentiation or alcohol index.
ApoA-I, a major HDL component in serum, is synthe-
sized in the liver and small intestine, and constitutes
Table 3 Univariate and multivariate cox analysis for overall survival in patients with ESCC
Variables Univariate analysis Multivariate analysis
HR 95 % CI p Value HR 95 % CI p Value
Sex
Male vs. Female 1.376 0.918–2.063 0.123
Age
<58 vs. ≥58 1.008 0.712–1.428 0.965
pT status
T1-2 vs. T3-4 0.453 0.288–0.712 0.001
pN status
Yes vs. No 0.416 0.292–0.594 0.000
pM status
Yes vs. No 0.401 0.220–0.729 0.003
pTNM status
I–II vs. III–IV 0.412 0.289–0.587 0.000 0.427 0.299–0.609 0.000
Histological differentiation
Differentiated vs. Undifferentiated 0.907 0.227–3.722 0.907
Tobacco index
Yes vs. No 0.762 0.528–1.101 0.147
Alcohol index
Yes vs. No 0.65 0.458–0.921 0.015 0.688 0.484–0.977 0.037
ApoA-I (g/L)
<1.21 vs. ≥1.21 1.541 1.082–2.193 0.016 1.519 1.021–2.261 0.039
ApoB(g/L)
<1.00 vs. ≥1.00 0.927 0.654–1.313 0.669
HDL-C(mmol/L)
<1.20 vs. ≥1.20 0.993 0.701–1.407 0.968
LDL-C(mmol/L)
<3.38 vs. ≥3.38 0.935 0.659–1.327 0.707
TC(mmol/L)
<4.89 vs. ≥4.89 1.041 0.734–1.475 0.824
TG(g/L)
<1.10 vs. ≥1.10 1.111 0.784–1.574 0.554
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approximately 70 % of the apolipoprotein content of
HDL particles [21]. Chylomicrons contain ApoA-I,
which is quickly transferred to HDL in the bloodstream
after being secreted from intestinal enterocytes [22].
ApoA-I is a critical player in reverse cholesterol trans-
port by extracting cholesterol from tissues and transfer-
ring it to the liver for its excretion. Cholesterol is a
cofactor for lecithin cholesterol acyltransferase, which is
responsible for the formation of most plasma cholesteryl
esters [23]. ApoA-I is overexpressed in patients with re-
current head and neck squamous cell carcinoma [17].
However, ApoA-I levels are decreased in the serum of
patients with pancreatic cancer, colorectal cancer, and
ovarian cancer [13, 24, 25]. Low ApoA-I levels are asso-
ciated with a high cancer risk, specifically with recur-
rence in breast cancer [8, 26]. Similarly, our study
showed that a low ApoA-I level is strongly correlated
with poor OS and is an independent prognostic factor
for survival (HR: 1.519; 95 % CI: 1.021–2.261).
However, the role of ApoA-I in carcinogenesis is not
well understood. In addition to the known functions of
ApoA-I, it also possesses anti-inflammatory and antioxi-
dant properties. The group of Farias-Eisner showed that
ApoA-I mimetic peptides affect tumor growth and de-
velopment in mouse models of colon cancer and ovarian
cancer [27, 28]. These studies can help establish an asso-
ciation between ApoA-I and ESCC. Lysophospholipids,
such as lysophosphatidic acid (LPA), are well-known ac-
tivators of proliferation in many cancers. A plausible
mechanism is that ApoA-I binds LPA to inhibit LPA-
induced cell growth. Hazen et al. demonstrated that in
the tumor microenvironment, ApoA-I may be work as a
potent immunomodulatory agent, altering tumor-
associated macrophages from a pro-tumor to an antitu-
mor phenotype [29]. Consistent with these studies, our
results showed that patients with low ApoA-I levels had a
significantly poor 5-year OS; however, further research is
needed to clarify the underlying mechanisms.
In our study, a low alcohol index was a significant in-
dependent predictor of favorable OS in ESCC patients
(HR: 0.688, 95 % CI: 0.484–0.977). These findings are
consistent with previous studies showing a strong associ-
ation between alcohol consumption and increased risk
of ESCC [30, 31]. There is strong epidemiological evi-
dence that consumption of alcoholic beverages increases
the risk of cancers of the oral cavity and pharynx,
esophagus, and larynx. Accumulating evidence indicates
that acetaldehyde is predominantly responsible for the
alcohol associated carcinogenesis, since acetaldehyde is
carcinogenic, mutagenic, binds to DNA and protein,
destroys folate, and results in secondary hyper-
regeneration [32]. A number of plausible mechanisms
have been proposed, including the relation between alco-
hol drinking and TC, HDL-C, and apolipoproteins; how-
ever, none of these has as yet been firmly established. In
the present study, alcohol index was not significantly dif-
ferent between the two categorical ApoA-I groups
(Table 1). These results indicated that alcohol consump-
tion was not correlated with ApoA-I concentration.
Further studies are needed to clarify these mechanisms.
Although ApoA-I was reported to be a prognostic fac-
tor in several malignancies [33], an association between
ApoA-I and prognosis in ESCC patients has not been
reported to date. In this study, the ApoA-I level was
lower in ESCC patients than in normal controls, both
ApoA-I and alcohol consumption are independent pre-
dictor of OS. Furthermore ApoA-I could function as an
independent prognostic factor of ESCC, also it is a com-
mon and convenient monitoring index in routine pre-
operative examination.
Fig. 2 Analysis of 5-year overall survival in ESCC patients. Kaplan–Meier survival curves for overall survival of ESCC patients showing significantly
poor survival with higher p TNM status (a), alcohol index (b) and lower ApoA-I (c)
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Conclusions
To our knowledge, this is the first retrospective study
investigating the relationship between pre-therapy serum
lipids and lipoproteins and ESCC. ApoA-I concentration
is an independent favorable prognostic factor in ESCC;
it shows high reproducibility and can easily be measured
in all diagnostic laboratories. Further, we also demon-
strated that alcohol consumption influences the survival
of patients with ESCC. As this study is a retrospective
analysis, it is only valid for generating a hypothesis, and
the value of ApoA-I should be validated in large pro-
spective trials.
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